Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

被引：0
|
作者：
Reid, A. [1 ]
Attard, G. [1 ]
Oommen, N. Babu [1 ]
Olmos, D. [1 ]
Fong, P. [1 ]
Molife, R. [1 ]
Dowsett, M. [2 ]
Lee, G. [3 ]
Molina, A. [3 ]
De-Bono, J. S. [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London, England
[2] Acad Dept Biochem, Royal Marsden NHS Fdn Trust, London, England
[3] Cougar Biotechnol Inc, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)71958-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [11] Safety of abiraterone acetate (AA) in castration-resistant prostate cancer (CRPC) patients with concomitant cardiovascular disease.
    Procopio, Giuseppe
    Verzoni, Elena
    Testa, Isabella
    Biasoni, Davide
    Torelli, Tullio
    Nicolai, Nicola
    Salvioni, Roberto
    Valdagni, Riccardo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [12] The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).
    Harshman, Lauren Christine
    Werner, Lillian
    Nakabayashi, Mari
    Tripathi, Abhishek
    Mckay, Rana R.
    Wang, Xiaodong
    Pomerantz, Mark
    Mucci, Lorelei A.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    Lee, Gwo-Shu Mary
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [13] Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC)
    Bianchini, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [14] Clinical benefit on abiraterone acetate (AA) in patients (pts) with PTEN loss castration-resistant prostate cancer (CRPC)
    Omlin, A.
    Pezaro, C.
    Reid, A.
    Rodrigues, D. Nava
    Riisnaes, R.
    Miranda, S.
    Tunariu, N.
    Lorente, D.
    Attard, G.
    De Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S707 - S707
  • [15] Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
    Eisenberger, Mario A.
    EUROPEAN UROLOGY, 2009, 55 (01) : 248 - 248
  • [16] Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1124 - 1124
  • [17] Re: Phase I Clinical Trial of a Selective inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
    Schalken, Jack A.
    EUROPEAN UROLOGY, 2008, 54 (06) : 1438 - 1439
  • [18] Abiraterone acetate for castration resistant prostate cancer
    Shah, Shreya
    Ryan, Charles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (04) : 563 - 570
  • [19] The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models.
    Moore, William R.
    Maity, Sankar N.
    Eisner, Joel Robert
    Garvey, Edward P.
    Hoekstra, William J.
    Titus, Mark Anton
    Logothetis, Christopher
    Araujo, John C.
    Efstathiou, Eleni
    Schotzinger, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [20] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345